secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001493152-23-013781
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx appoints former Schering-Plough CMO Robert Spiegel to board
--------------------------------------------------------------------

- Dr. Spiegel appointed as independent director effective April 25, 2023; board size increased from 6 to 7.
- He brings 40+ years biopharma experience, involved in over 30 FDA NDA approvals and multiple blockbuster drugs.
- Received initial option award for 43,026 shares valued at $120,000, vesting monthly over 36 months.
- Company plans to advance FDA discussions on RenovoGem Phase III interim data and new indications.
- Dr. Spiegel also serves on boards of Geron, Cyclacel, Ayala, Athenex, and SPARC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/0001493152-23-013781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-013781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer